(1)Comprehensive Cancer Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland. (2)Department of Plastic Surgery, Helsinki University Hospital and University of Helsinki, Helsinki, Finland. (3)Dept of Pathology, HUSLAB and University of Helsinki, Helsinki, Finland. (4)Dept of Medical Diagnostics, School of Health Sciences, Orebro University, Orebro, Sweden. (5)Dept of Surgery, Helsinki University Hospital and University of Helsinki, Helsinki, Finland. (6)Reseach Program Unit, Translational Cancer Biology, University of Helsinki, Helsinki, Finland. (7)Dept of Oncology, Orebro University Hospital, Orebro, Sweden.
Publication
J Surg Oncol
Summary
We investigated the prognostic role of cyclin A and Ki67 in desmoid tumors by immunohistochemistry. The study included 76 patients with desmoid tumor operated at Helsinki University Hospital between 1987 and 2011. A tissue micro array (TMA) was constructed and the TMA sections were immunostained with cyclin A and Ki67 antibodies. Cyclin A expression correlated significantly with Ki67. Cyclin A expression was associated with recurrence-free survival (HR 1.9, 95% CI = 1.1-3.2, P = .02), as were positive margin (HR 6.0, 95% CI = 1.6-22.5, P = .008) and extremity location (HR 5.3, 95% CI = 1.7-16.8, P = 0.005). Ki67 immunopositivity varied from 0.33% to 13.8%, with a mean of 4.6%, but had no significant prognostic impact (HR 1.1, P = .2). Our study indicates that cyclin A may be a new prognostic biomarker in surgically treated desmoid tumors.
Stay Up to Date as We Uncover More About Desmoid Tumors
